EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Efficacy and Safety of Romiplostim Versus Placebo in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis

Humayou Ahmed iD, Muhammad Saad Khan iD, Daniyal Zulfiqar, Kainat Mehmood iD, Kanza Farhan, Syed Ali Hassan, Fiza Shaikh, Umarah Lutuf, Aqsa, Aminath Waafira iD

Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32

DOI: 10.1177/10760296261476820 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 06.08.2026. Verfasst von Humayou Ahmed und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan. Hauptthemen laut MEDLINE: Thrombopoietin, Recombinant Fusion Proteins, Receptors, Fc, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia and increased bleeding risk. Although first-line therapies such as corticosteroids and intravenous immunoglobulin provide initial benefit, many patients relapse or develop refractory disease. Romiplostim, a thrombopoietin receptor agonist, has emerged as an effective second-line therapy; however, evidence comparing its efficacy and safety with placebo across both pediatric and adult populations remains limited.

Methods

A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted following PRISMA guidelines (PROSPERO: CRD420261357179). PubMed, Scopus, Cochrane Library, and Google Scholar were searched up to March 2026. RCTs comparing romiplostim with placebo in ITP patients were included. A random-effects model was used to calculate mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI). Risk of bias was assessed using the Cochrane RoB 2 tool. Certainty of evidence was evaluated using the GRADE approach.

Results

Nine RCTs (n=748) were included. Romiplostim significantly increased platelet counts at week 2 (MD 25.71; 95% CI 9.41–42.02), week 4 (MD 42.74; 95% CI 26.82–58.66), week 6 (MD 50.42; 95% CI 33.87–66.97), and week 8 (MD 49.14; 95% CI 20.45–77.83), with larger effects in adults. Platelet response rates were significantly higher with romiplostim (RR 6.10). The proportion achieving ≥20×10 9 /L increase improved (RR 3.23), and the need for rescue therapy decreased (RR 0.49). Adverse events were comparable between groups, with slight increases in myalgia and rash.

Conclusion

Romiplostim is an effective and well-tolerated therapy for ITP, significantly improving platelet outcomes and reducing rescue therapy requirements without major safety concerns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombopoietinRecombinant Fusion ProteinsReceptors, FcPurpura, Thrombocytopenic, IdiopathicHumansRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

immune thrombocytopeniameta-analysisplatelet countromiplostimthrombopoietin receptor agonist

Substanzen

romiplostimThrombopoietinRecombinant Fusion ProteinsReceptors, Fc

Autor:innen und Institutionen

  • Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
  • Department of Medicine, Peoples University of Medical and Health Sciences for Women, Shaheed Benazirabad, Pakistan.
  • Department of Medicine, Liaquat University of Health Sciences, Jamshoro, Pakistan.
  • Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan.
  • Department of Medicine, School of Medicine, The Maldives National University, Malé, Maldives.

ORCID-Profile: Humayou Ahmed, Muhammad Saad Khan, Kainat Mehmood, Aminath Waafira

Zitieren

APA

Ahmed, H., Khan, M. S., Zulfiqar, D., Mehmood, K., Farhan, K., Hassan, S. A., Shaikh, F., Lutuf, U., Aqsa, & Waafira, A. (2026). Efficacy and Safety of Romiplostim Versus Placebo in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261476820

Vancouver

Ahmed H, Khan MS, Zulfiqar D, Mehmood K, Farhan K, Hassan SA, et al. Efficacy and Safety of Romiplostim Versus Placebo in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261476820

BibTeX
@article{Ahmed2026,
  author = {Ahmed, Humayou and Khan, Muhammad Saad and Zulfiqar, Daniyal and Mehmood, Kainat and Farhan, Kanza and Hassan, Syed Ali and Shaikh, Fiza and Lutuf, Umarah and Aqsa and Waafira, Aminath},
  title = {Efficacy and Safety of Romiplostim Versus Placebo in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2026},
  volume = {32},
  doi = {10.1177/10760296261476820}
}
Kostenlos starten →